Patient and Graft Survival After Pre-emptive Versus Non-pre-emptive Kidney Transplantation: A Single-Center Experience From Turkey


Bozkurt B., Kumru A. O., Dumlu E. G., Tokac M., KOÇAK H., SÜLEYMANLAR G., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.45, sa.3, ss.932-934, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.transproceed.2013.02.064
  • Dergi Adı: TRANSPLANTATION PROCEEDINGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.932-934
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objective. We sought to report the graft and patients survival of pre-emptive and non-pre-emptive kidney transplantations performed in our center.

OBJECTIVE:

We sought to report the graft and patients survival of pre-emptive and non-pre-emptive kidney transplantations performed in our center.

METHODS:

The 859 subjects showed a mean age of 36.1 years and included 64.6%; males, who received grafts from living (n = 665) or deceased (n = 194) donors between January 2008 and June 2011. We reviewed their medical records retrospectively, to separately pre-emptive versus non-pre-emptive recipients for year transplant outcomes.

RESULTS:

Among the 859 patients, 153 (17.8%) underwent pre-emptive and 706 (82.2%), non-pre-emptive kidney transplantations. The rate of living donors was higher in the pre-emptive group (97.4% vs 73%, respectively). The 1-year graft survivals were 99.3% and 95.8% in pre-emptive and non-pre-emptive transplantation groups, respectively (P > .05). There was no significant difference between groups with respect to patient survival at 1 year (P > .05).

CONCLUSION:

In conclusion, graft and patient survival rates between pre-emptive and non-pre-emptive kidney transplantation cases were comparable at 1 year. Pre-emptive kidney transplantation, which eliminates hemodialysis costs and complications, should be preferred as the optimal renal replacement therapy for end-stage renal disease patients.